In the four ESCC cells, the combination of gefitinib and linsitinib could not only significantly reduce the activation of EGFR, HER2, IGF-1R, AKT, and ERK, but it also had a stronger inhibitory effect than any single drugs. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.